Roth Capital Issues Negative Estimate for MNMD Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Investment analysts at Roth Capital cut their Q3 2025 earnings per share estimates for Mind Medicine (MindMed) in a research note issued on Tuesday, November 19th. Roth Capital analyst J. Wittes now expects that the company will earn ($0.35) per share for the quarter, down from their prior estimate of ($0.34). The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.25) per share. Roth Capital also issued estimates for Mind Medicine (MindMed)’s FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.61) EPS, FY2027 earnings at $1.27 EPS and FY2028 earnings at $4.67 EPS.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $55.00 price objective on shares of Mind Medicine (MindMed) in a report on Monday, November 11th. Leerink Partnrs raised Mind Medicine (MindMed) to a “strong-buy” rating in a research report on Friday, October 11th. Leerink Partners assumed coverage on shares of Mind Medicine (MindMed) in a research report on Monday, October 14th. They set an “outperform” rating and a $20.00 price objective on the stock. Finally, Canaccord Genuity Group lowered their price target on Mind Medicine (MindMed) from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Nine investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mind Medicine (MindMed) has an average rating of “Buy” and a consensus price target of $25.38.

Mind Medicine (MindMed) Stock Up 6.6 %

Shares of Mind Medicine (MindMed) stock opened at $7.56 on Friday. Mind Medicine has a 1 year low of $2.75 and a 1 year high of $12.22. The firm has a market cap of $554.37 million, a price-to-earnings ratio of -3.35 and a beta of 2.48. The company has a 50-day moving average of $6.44 and a 200 day moving average of $7.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00.

Insider Activity at Mind Medicine (MindMed)

In other Mind Medicine (MindMed) news, insider Dan Karlin sold 6,871 shares of Mind Medicine (MindMed) stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $5.98, for a total value of $41,088.58. Following the sale, the insider now directly owns 344,656 shares in the company, valued at approximately $2,061,042.88. The trade was a 1.95 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert Barrow sold 19,771 shares of the stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $5.98, for a total transaction of $118,230.58. Following the transaction, the chief executive officer now directly owns 545,772 shares of the company’s stock, valued at $3,263,716.56. This trade represents a 3.50 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,994 shares of company stock worth $173,384. 2.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On Mind Medicine (MindMed)

A number of hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in Mind Medicine (MindMed) by 472.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 246,208 shares of the company’s stock worth $1,775,000 after acquiring an additional 203,216 shares during the last quarter. Tidal Investments LLC bought a new position in Mind Medicine (MindMed) during the first quarter valued at $1,698,000. Rhumbline Advisers purchased a new position in shares of Mind Medicine (MindMed) in the 2nd quarter worth $679,000. Janus Henderson Group PLC bought a new stake in shares of Mind Medicine (MindMed) in the 1st quarter worth about $8,964,000. Finally, Marshall Wace LLP raised its position in shares of Mind Medicine (MindMed) by 8.1% during the 2nd quarter. Marshall Wace LLP now owns 2,160,203 shares of the company’s stock valued at $15,575,000 after buying an additional 161,659 shares in the last quarter. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.